RxDoctor Payments Data

Ramaiah Indudhara, MD

Urology · Brawley, CANPI 1538116215

Payments from drug & device makers

$20,024in general payments, 2019–2025

Across 143 payments — averaging $140.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$13K
  • Palette Life Sciences, Inc.$2K
  • Teleflex LLC$1K
  • Neotract Inc.$1K
  • Astellas Pharma US Inc$881
  • AstraZeneca$292
  • plus $2K from 22 others

What the payments were for

  • Speaking & faculty fees$2501%
  • Travel & lodging$3,88819%
  • Food & beverage$4,16421%
  • Education$11,72259%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,024 in reported general payments places this provider in the 80th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$132,226
Medicare patients
473
Services billed
1,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide31$449,566
MyrbetriqMirabegron24$16,216
GemtesaVibegron13$10,862
Tamsulosin Hcl237$5,278
Oxybutynin Chloride ErOxybutynin Chloride219$3,669
Dutasteride30$1,784
Potassium Citrate ErPotassium Citrate22$1,487
Estradiol14$1,243
Finasteride57$1,186
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst23$830
NitrofurantoinNitrofurantoin Macrocrystal22$739
Lactulose50$683
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen79$389
Ciprofloxacin Hcl104$367
Cephalexin57$285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$881$465,78255 claims
Sumitomo Pharma America, Inc.Gemtesa$175$10,86213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,324 urology providers in California.

Other urology in Brawley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →